Global Xerostomia Therapeutics Market Trends, Forecast Report 2025-2037
Xerostomia Therapeutics Market size was over USD 1.3 billion in 2024 and is likely to exceed USD 2.5 billion by the end of 2037, growing at over 6.2% during the forecast period i.e., between 2025-2037. In 2025, the industry size of xerostomia therapeutics is assessed at USD 1.5 billion.
The xerostomia therapeutics market is witnessing expansion owing to the growing burden of drug-induced dry mouth, Sjögren’s syndrome, and an increase in the aging demographics. The National Institute of Health report in 2024 estimates that above 22% of adults who are over 65 suffer from chronic symptoms. Besides, the Sjögren’s Foundation in 2023 stated that autoimmune conditions such as Sjögren’s syndrome affect 4.3 million individuals in the U.S., meanwhile, 42% to 55% of cancer patients who received radiotherapy are more likely to develop severe dry mouth. Therefore, these rising instances enhance the demand for xerostomia therapeutics for which APIs are primarily being sourced from China and India, i.e., 40% and 30%.
Further, the growth in this sector is stimulated by the presence of the supply chain aspect, which is fueled by the U.S. and EU-based firms that supply 80% of OTC saliva substitutes. Meanwhile, the producer price index of xerostomia drugs has increased by 3.5% due to the regulatory compliance. Simultaneously, the consumer price index witnessed an annual rise of 5.4% owing to the heightened demand, thus ensuring global elasticity. According to the USITC data in 2024, the U.S. is the major importer of xerostomia APIs, which grew by 13.7% year over year in 2023, further denoting a strong necessity.
Xerostomia Therapeutics Sector: Growth Drivers and Challenges
Growth Drivers
- Advancements in drug innovations: This is one of the primary drivers in the xerostomia therapeutics market, as the worldwide population is disproportionately affected by dry mouth. In this regard, Eisai Co. Ltd. in 2024 launched EVOXAC (cevimeline) in chewable form, which remarkably improved compliance by 42%. Besides, it is reported that phase II stem cell therapy trials for salivary gland regeneration demonstrated a 52% symptom reduction, fostering a positive outlook for this sector.
- Improvements in healthcare quality: This is yet another driver that positively impacts the xerostomia therapeutics market across all nations. As stated by the AHRQ report in 2022, an early intervention with saliva stimulants reduced hospitalizations by 22.4%, saving approximately USD 1.2 billion in the U.S. healthcare expenditure over two years. Further, in Germany, the Disease Management Program for Sjögren’s syndrome improved xerostomia treatment adherence by 30.5%, thereby lowering complications.
Historical Patient Growth and Its Impact on Xerostomia Therapeutics Market Expansion
The xerostomia therapeutics market is fundamentally undergoing modification owing to the aspect of steady rise in the patient pool over the last decade. Besides, there is a surge in aging demographics, autoimmune diseases, and growing incorporation of xerostomia-inducing medications such as antihypertensives and antidepressants. This expansion in terms of the patient pool has directly benefited manufacturers and suppliers in aspect of revenue, particularly in established nations, as there is higher treatment accessibility. Simultaneously in emerging markets are witnessing unmet medical needs, encouraging the key players to invest in this sector.
Historical Patient Growth (2010–2020) in Key Markets
|
Country |
2010 Patients (Million) |
2020 Patients (Million) |
Growth Rate (%) |
|
U.S. |
4.5 |
8.1 |
85.9% |
|
Germany |
1.3 |
2.7 |
118.4% |
|
France |
1.2 |
1.9 |
89.2% |
|
Spain |
0.8 |
1.5 |
116.9% |
|
Australia |
0.6 |
1.2 |
125.2% |
|
Japan |
2.5 |
4.3 |
78.5% |
|
India |
3.7 |
6.4 |
77.3% |
|
China |
5.6 |
12.4 |
114.2% |
Manufacturer Strategies Driving Xerostomia Therapeutics Market Expansion
Manufacturers involved in the xerostomia therapeutics market leverage product innovation in the form of chewable formulations and biologics, collaborations with oncology units, and expansion into emerging markets with a collective goal to strengthen their market positions. Esai Co. Ltd captured a 13.6% additional market share in 2023 with the launch of chewable tablets addressing compliance issues in elderly patients. Meanwhile, in the U.S., GSK’s Biotene announced a partnership with dental clinics to enhance OTC products with radiotherapy post care, thereby accelerating the revenue by USD 181 million. Hence, these tactics have reshaped the competitive landscape, pushing smaller players to focus on niche segments such as pediatric xerostomia.
Revenue Growth Opportunities for Xerostomia Manufacturers (2023–2025)
|
Company |
Strategy |
Revenue Impact (2023) |
Market Share Change |
|
Eisai Co. |
Chewable EVOXAC launch |
+$221.2 million |
+13.6% |
|
GSK |
Dental clinic partnerships |
+$181 million |
+8.7% |
|
Sun Pharma |
India generic expansion |
+$91.8 million |
+5.6% |
|
P&G |
Biotène® telehealth kits |
+$72.3 million |
+4.8% |
Challenge
- Barriers in regulatory procedures: The major challenge causing hindrance to the xerostomia therapeutics market is the delays in terms of stringent regulatory frameworks. In this regard, PMDA data in 2022 unveiled that in Japan, the saliva stimulant approvals were delayed by 6 months owing to the strict safety reviews. Further, in 2023, the U.S. FDA’s backlog for medical devices such as electrostimulation tools pushed the launch to 2025, making it challenging for xerostomia manufacturers to leverage the therapeutics.
Xerostomia Therapeutics Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.2% |
|
Base Year Market Size (2024) |
USD 1.3 billion |
|
Forecast Year Market Size (2037) |
USD 2.5 billion |
|
Regional Scope |
|
Xerostomia Therapeutics Segmentation
Treatment Type (Saliva Substitutes, Salivary Stimulants, Dentifrices)
The salivary stimulants segment is anticipated to register the largest share of 42.8% in the xerostomia therapeutics market during the forecast period. The dominance of this segment is highly attributed to the continuous and rigorous occurrence of Sjögren’s syndrome among the worldwide population. In the U.S., above 3.9 million individuals are diagnosed with the disease, out of which 81.4% are reported to be severe, reflecting a sustained demand for stimulants such as pilocarpine and cevimeline. Besides, the U.S. FDA prioritized chewable cevimeline, extending its contribution for the segment’s leadership by reducing dosing frequency and improving compliance.
Drug Class (Cholinergic Agonists, Local Anti-inflammatory Agents)
The cholinergic agonists segment is projected to register considerable growth in the xerostomia therapeutics market by 2037. The growth in the segment is primarily subject to its affordability, the aging demographics, and the generic boom in emerging countries. ICMR reports in 2024 state that generic pilocarpine tablets cost USD 0.55 per dose to USD 16.5 per dose for biologics, making them the first-line therapy in emerging markets. Further, WHO projects a 5.9% CAGR in terms of agonists owing to above 490 million elderly population by 2030. Sun Pharma and CSPC Pharma control 61.7% of Asia’s pilocarpine supply with a focus on cutting prices.
Our in-depth analysis of the global xerostomia therapeutics market includes the following segments:
|
Treatment type |
|
|
Drug Class |
|
|
Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportXerostomia Therapeutics Industry - Regional Synopsis
North America Market Analysis
North America is a key player in the xerostomia therapeutics market, projected to register a significant share of 45.7% in 2037. The leadership of the region is attributed to the increasing disease prevalence, i.e., 4.2 million patients, and the enhanced Medicare coverage. CMS report published in 2024 states that federal healthcare expenditure on dry mouth therapies reached USD 1.9 billion in 2023, with Medicaid particularly allocating USD 522 million, thus reflecting a mounting support. This, coupled with FDA fast tracks and telehealth programs, are the amplifiers for this landscape.
Canada’s xerostomia therapeutics market is growing exponentially, rising at a CAGR of 5.8%, powered by the aging demographics and enhanced healthcare investments. CIHI data in 2024 unveiled that there will be a 20% geriatric population by 2030. Further, Ontario’s allocation of USD 220.3 million on dry mouth treatments and 86% for Sjögren’s patients fosters a favorable business environment for this merchandise. Domination of generic pilocarpine and intensified demand in rural areas affiliates for growth in the industry.
Europe Market Statistics
Europe is projected to grow at a lucrative rate, with the second largest share of 28.3% in the xerostomia therapeutics market during the assessed time frame. The region benefits from a substantial number of assorted and aging population, which outstretches the significance of the market. Germany is at the forefront of this upliftment, leading with €4.3 billion in annual expenditure, meanwhile, the EU Health Fund allocated € 2.6 billion for dry mouth research. Therefore, these factors utterly support market development in the region.
The U.K. is one of the largest contributors to growth in the regional xerostomia therapeutics market, capturing 25.8% share in the Europe market. As evidence NHS’s 2025 Oral Health Strategy prioritizes xerostomia, allocating £200.4 million for OTC product subsidies. Besides, the Association of the British Pharmaceutical Industry report published in 2024 reports a 12% annual growth in stimulant prescriptions owing to cancer therapy partnerships. This indicates the presence of an extended support of both public and private systems, representing a suitable landscape for the business to expand.
Companies Dominating the Xerostomia Therapeutics Landscape
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The presence of both established and emerging players in the industry is fostering a standard landscape for the xerostomia therapeutics market to escalate. Global leaders such as GSK, Colgate-Palmolive, and Johnson & Johnson are leading the market with their brand recognition and extensive distribution. Besides, emerging nations such as India and Malaysia are witnessing growth owing to the presence of generic manufacturers such as Sun Pharma and Cipla. Further, firms are focused on research in saliva substitutes and investments in terms of biotech solutions to capture niche markets.
Here is a list of key players operating in the global market:
|
Company Name |
Country of Origin |
Market Share |
Industry Focus |
|
GlaxoSmithKline plc |
UK |
13.8% |
Biotene line (mouthwashes, gels, toothpaste for dry mouth relief). |
|
Colgate-Palmolive Company |
U.S. |
11.2% |
Colgate Hydris (dry mouth-specific oral care products). |
|
Johnson & Johnson |
U.S. |
10.5% |
Saliva substitutes, oral moisturizers (e.g., NeutraSal). |
|
Sun Pharmaceutical Industries |
India |
9.3% |
Generic & branded xerostomia medications. |
|
Eisai Co., Ltd. |
Japan |
8.2% |
Prescription-based dry mouth treatments (e.g., for Sjögren’s syndrome). |
|
Novartis AG |
Switzerland |
xx% |
Advanced salivary stimulants & novel drug formulations. |
|
Pfizer Inc. |
U.S. |
xx% |
Radiation-induced xerostomia therapies. |
|
Bayer AG |
Germany |
xx% |
Over-the-counter dry mouth relief products. |
|
Procter & Gamble |
U.S. |
xx% |
Oral-B dry mouth rinses & gels. |
|
Takeda Pharmaceutical |
Japan |
xx% |
Treatments for autoimmune-related xerostomia (e.g., Sjögren’s). |
|
Sanofi S.A. |
France |
xx% |
Salivary gland therapies & partnerships with dental clinics. |
|
AstraZeneca plc |
UK |
xx% |
Novel drug formulations for chronic dry mouth. |
|
Merck & Co., Inc. |
U.S. |
xx% |
Biologic treatments under development. |
|
Hikma Pharmaceuticals PLC |
UK |
xx% |
Generic oral mucositis & dry mouth medications. |
|
CSL Limited |
Australia |
xx% |
Biotech-driven saliva stimulation therapies. |
|
LG Chem Ltd. |
South Korea |
xx% |
Innovative oral hydration solutions & medical devices. |
|
Cipla Ltd. |
India |
xx% |
Affordable dry mouth care products for emerging markets. |
|
Dabur India Ltd. |
India |
xx% |
Ayurvedic-based remedies (e.g., herbal mouth sprays). |
|
Duopharma Biotech Berhad |
Malaysia |
xx% |
Regional oral healthcare solutions (e.g., saliva substitutes). |
|
Aspen Pharmacare Holdings |
South Africa |
xx% |
Specialized formulations for Australia & Southeast Asia. |
Below are the areas covered for each company under the top 15 global manufacturers:
Recent Developments
- In May 2024, Colgate-Palmolive launched Hydris Pro-Moisture mouthwash, which is a pH-balanced, alcohol-free mouthwash designed for chronic dry mouth sufferers, featuring hyaluronic acid for mucosal repair.
- In March 2024, GlaxoSmithKline launched Biotene Advanced Oral Hydration Gel, expanding its Biotene line with a longer-lasting oral hydration gel, clinically proven to provide 12-hour dry mouth relief.
Author Credits: Radhika Pawar
- Report ID: 2959
- Published Date: Jun 05, 2025
- Report Format: PDF, PPT
